Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats.
OBJECTIVE
Carbon tetrachloride (CCl4) is a lipid-soluble potent hepatotoxic; thus, it widely is used as an animal model of severe hepatic failure. Treatment with antioxidants may modulate the toxic effects of CCl4 on liver, generally with drug administration before CCl4, which can restrict its use in the clinical setting. We here describe the effects of N-acetylcysteine, deferoxamine, or both in the treatment of CCl4-induced hepatic failure.


METHODS
Prospective, randomized, controlled experiment.


METHODS
Animal basic science laboratory.


METHODS
Male Wistar rats, weighing 200-250 g.


METHODS
Rats exposed to CCl4 were treated with N-acetylcysteine and/or deferoxamine or vehicle.


RESULTS
N-acetylcysteine plus deferoxamine treatment significantly attenuated hepatic and central nervous system oxidative damage after acute hepatic failure induced by CCl4. In addition, the serum levels of alanine aminotransferase, total bilirubin, and prothrombin time in the N-acetylcysteine plus deferoxamine group were significantly lower than those in the N-acetylcysteine or deferoxamine and saline groups. After N-acetylcysteine plus deferoxamine treatment, hepatocellular necrosis and inflammatory infiltration induced by carbon tetrachloride were greatly decreased. Survival in untreated rats was 5%. Survival increased to 25% and 35%, respectively, with N-acetylcysteine and deferoxamine treatment. In rats treated with N-acetylcysteine plus deferoxamine, survival was 80%.


CONCLUSIONS
Our data provide the first experimental demonstration that N-acetylcysteine plus deferoxamine reduces mortality rate, decreases oxidative stress, and limits inflammatory infiltration and hepatocyte necrosis induced by CCl4 in the rat.
Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, SC, Brazil.
Cristiane
C
Ritter
Adalisa
A
Reinke
Michael
M
Andrades
Márcio Rodrigo
MR
Martins
João
J
Rocha
Sérgio
S
Menna-Barreto
João
J
Quevedo
José Cláudio F
JC
Moreira
Felipe
F
Dal-Pizzol
D000111:Acetylcysteine / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D002251:Carbon Tetrachloride / Q000009:adverse effects; D003676:Deferoxamine / Q000494:pharmacology* / Q000627:therapeutic use; D006838:Hydrocarbons / Q000009:adverse effects; D007249:Inflammation; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D017114:Liver Failure, Acute / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D023421:Models, Animal; D009336:Necrosis; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; D006838:Hydrocarbons; D002251:Carbon Tetrachloride; D003676:Deferoxamine; D000111:Acetylcysteine